Price Action Report: Novo Nordisk A S (ADR)’s Stock Is Sell After Achieving 1 Year Low

Price Action Report: Novo Nordisk A S (ADR)'s Stock Is Sell After Achieving 1 Year Low

The stock of Novo Nordisk A S (ADR) (NYSE:NVO) hit a new 52-week low and has $30.34 target or 6.00% below today’s $32.28 share price. The 7 months bearish chart indicates high risk for the $64.76B company. The 1-year low was reported on Nov, 21 by If the $30.34 price target is reached, the company will be worth $3.89B less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 3.44M shares traded hands. Novo Nordisk A S (ADR) (NYSE:NVO) has declined 43.63% since April 19, 2016 and is downtrending. It has underperformed by 47.49% the S&P500.

Novo Nordisk A S (ADR) (NYSE:NVO) Ratings Coverage

Out of 13 analysts covering Novo Nordisk (ADR) (NYSE:NVO), 3 rate it a “Buy”, 2 “Sell”, while 8 “Hold”. This means 23% are positive. Novo Nordisk (ADR) has been the topic of 13 analyst reports since August 28, 2015 according to StockzIntelligence Inc. The rating was downgraded by JP Morgan to “Neutral” on Friday, September 9. On Tuesday, September 13 the stock rating was upgraded by BNP Paribas to “Outperform”. The rating was downgraded by Morgan Stanley to “Equal-Weight” on Thursday, September 1. The stock has “Strong Buy” rating given by Jyske Bank on Monday, October 19. The firm has “Sell” rating given on Monday, February 8 by UBS. The firm has “Neutral” rating given on Friday, September 23 by Piper Jaffray. The rating was initiated by Leerink Swann with “Market Perform” on Friday, August 28. As per Wednesday, August 31, the company rating was upgraded by HSBC. As per Monday, February 15, the company rating was upgraded by Goldman Sachs. The stock of Novo Nordisk A S (ADR) (NYSE:NVO) earned “Hold” rating by Zacks on Friday, August 28.

According to Zacks Investment Research, “Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world’s largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural resources.”

More news for Novo Nordisk A S (ADR) (NYSE:NVO) were recently published by:, which released: “Plus the latest data from on 21 home markets across the US” on July 03, 2009.‘s article titled: “DOW JONES, A NEWS CORP COMPANY” and published on February 11, 2011 is yet another important article.

NVO Company Profile

Novo Nordisk A/S, incorporated on November 28, 1931, is a healthcare company. The Firm is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company’s business divisions include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. The biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment